October 1, 2020 — According to our Q3 2020 survey of biotech and pharma thought leaders, over 90% experienced disruptions to trials in 2020. Respondents provided key insights into how this has shifted the paradigm for clinical, translational, and biomarker operations.
Biomarker-centric programs demand a focused strategy to provide timely visibility into sample availability and quality, data availability and quality, and critical on-study measurements.
